IRIDEX (NASDAQ:IRIX) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05, Fidelity Earnings reports. IRIDEX had a negative net margin of 26.02% and a negative return on equity of 39.42%. The company had revenue of $10.66 million for the quarter, compared to the consensus estimate of $10.08 million.
Shares of IRIDEX stock traded down $0.22 during trading hours on Friday, reaching $1.93. The company’s stock had a trading volume of 128,600 shares, compared to its average volume of 43,958. IRIDEX has a one year low of $1.50 and a one year high of $5.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 2.49 and a current ratio of 3.41. The company’s 50 day simple moving average is $1.88 and its 200 day simple moving average is $3.46. The stock has a market cap of $29.30 million, a P/E ratio of -1.84 and a beta of 0.80.
A number of research firms have recently issued reports on IRIX. Zacks Investment Research downgraded shares of IRIDEX from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. ValuEngine upgraded shares of IRIDEX from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser systems, which are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Featured Story: Real Estate Investment Trust (REIT) ETF
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.